Skip to main content
. 2023 Mar 8;12(6):832. doi: 10.3390/cells12060832

Figure 1.

Figure 1

Study design: (a) explore the role of sPD-L1, sB7-H3 and sB7-H4 as prognostic markers in patients with advanced NSCLC treated with nivolumab or pembrolizumab; (b) assess the involvement of EVs expressing PD-L1 and B7-H3 in the mechanisms of the response to ICIs.